Figure 3.
Figure 3. The BGLT3 locus is marked by chromatin signatures associated with enhancers. ChIP-qPCR for K562 cells with primers across BGLT3 using antibodies to CBP/p300 (A), H3K27ac (B), and H3K36me3 (C). (D) Ratio of the H3K4me1/H3K4me3 signal was determined from data obtained by ChIP-qPCR with antibodies to these modifications. Locations of BGLT3 primers are shown in Figure 1G; primer sequences are listed in supplemental Table 1; antibodies are listed in supplemental Table 2. (E) Ratio of the H3K4me1/H3K4me3 signal at BGLT3 or LCR HS2 was determined from data obtained by ChIP-qPCR with antibodies to these modifications using CRISPRi K562 cells targeted with (dCAS9/gRNA) or without (dCAS9) a specific gRNA. (F) ChIP-qPCR with primers for BGLT3 or LCR HS2 and antibodies to H3K27ac using CRISPRi K562 cells with (dCAS9/gRNA) or without (dCAS9) a specific gRNA. IgG, immunoglobulin G.

The BGLT3 locus is marked by chromatin signatures associated with enhancers. ChIP-qPCR for K562 cells with primers across BGLT3 using antibodies to CBP/p300 (A), H3K27ac (B), and H3K36me3 (C). (D) Ratio of the H3K4me1/H3K4me3 signal was determined from data obtained by ChIP-qPCR with antibodies to these modifications. Locations of BGLT3 primers are shown in Figure 1G; primer sequences are listed in supplemental Table 1; antibodies are listed in supplemental Table 2. (E) Ratio of the H3K4me1/H3K4me3 signal at BGLT3 or LCR HS2 was determined from data obtained by ChIP-qPCR with antibodies to these modifications using CRISPRi K562 cells targeted with (dCAS9/gRNA) or without (dCAS9) a specific gRNA. (F) ChIP-qPCR with primers for BGLT3 or LCR HS2 and antibodies to H3K27ac using CRISPRi K562 cells with (dCAS9/gRNA) or without (dCAS9) a specific gRNA. IgG, immunoglobulin G.

Close Modal

or Create an Account

Close Modal
Close Modal